Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Cancer Biomark. 2018;22(1):119-126. doi: 10.3233/CBM-171099.
miR-126 functions as a tumor suppressor in gastric cancer (GC), however, the clinical significance of serum miR-126 in GC remains unclear.
To investigate the associations of serum miR-126 level with the clinicopathological characteristics and prognosis of GC patients.
Quantitative real-time polymerase chain reaction was performed to examine the expression levels of miR-126 in 338 GC patients' tissues and sera, and 50 healthy controls' sera. The associations of serum miR-126 with clinicopathological characteristics and clinical outcome were evaluated.
Compared with the matched adjacent non-tumor tissues and normal sera, miR-126 expression was significantly down-regulated in both tumor tissues and sera of GC patients. Importantly, there was a positive correlation between tissue and serum levels of miR-126 in GC patients. A reduced serum miR-126 level statistically correlated with aggressive clinicopathological characteristics, such as larger tumor size, deeper local invasion, more lymph node metastasis, advanced TNM stage, and poorer prognosis. Notably, multivariate analysis identified reduced serum miR-126 level as an independent predictor for the unfavorable prognosis of GC.
These results indicate for the first time that serum miR-126 may serve as a novel prognostic biomarker in GC.
miR-126 在胃癌（GC）中作为一种肿瘤抑制因子发挥作用，然而，血清 miR-126 在 GC 中的临床意义尚不清楚。
探讨血清 miR-126 水平与 GC 患者临床病理特征及预后的关系。
采用实时定量聚合酶链反应检测 338 例 GC 患者组织和血清及 50 例健康对照者血清中 miR-126 的表达水平，评估血清 miR-126 与临床病理特征和临床结局的关系。
与配对的癌旁非肿瘤组织和正常血清相比，GC 患者的肿瘤组织和血清中 miR-126 的表达均明显下调。重要的是，GC 患者组织和血清中 miR-126 的水平呈正相关。血清 miR-126 水平降低与侵袭性临床病理特征显著相关，如肿瘤体积较大、局部浸润较深、淋巴结转移较多、TNM 分期较晚和预后较差。多因素分析表明，血清 miR-126 水平降低是 GC 预后不良的独立预测因素。
这些结果首次表明，血清 miR-126 可能是 GC 的一种新型预后生物标志物。
